The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | IFCT-1803 LORLATU cohort: real-world evidence supporting lorlatinib in ALK+ NSCLC
Nicolas Girard, MD, PhD, Institut Curie, Paris, France, discusses the results of the IFCT-1803 LORLATU cohort (NCT03727477) assessing treatment sequencing, and lorlatinib safety and efficacy in patients with ALK- and ROS1-positive non-small cell lung cancer (NSCLC). The real-world evidence demonstrated lorlatinib provides a notable clinical benefit in heavily pretreated patients with ALK-positive NSCLC. This interview took place during the virtual European Lung Cancer Congress 2022.
